EVENTS · UTHR
PEERS
EARNINGS
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for chronic and life-threatening conditions, with particular expertise in pulmonary arterial hypertension. Its current portfolio includes Tyvaso DPI and Tyvaso inhalation solution, Remodulin injection, Orenitram extended-release tablets, and Adcirca tablets, which address different treatment needs within pulmonary vascular disease. The company also markets Unituxin, a therapy used in the treatment of high-risk neuroblastoma. United Therapeutics combines pharmaceutical research, manufacturing, regulatory operations, and specialized commercial support to serve patients, healthcare professionals, hospitals, and specialty pharmacies. Its business is centered on rare and serious diseases where ongoing treatment and differentiated delivery methods are important, including inhaled, injectable, and oral formulations. The company also operates in regenerative medicine through technologies and programs related to organ transplantation and the development of organs suitable for clinical use. United Therapeutics Corporation therefore occupies a specialized role in biotechnology, linking innovative drug development with advanced approaches to address critical shortages in transplantable organs.
United Therapeutics Reports Third Quarter 2026 Financial Results with Revenue Up 4%
| Series | 1W | 1M |
|---|---|---|
| UTHR | +3.8% | +12.3% |
| Peers | +2.2% | +7.4% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 43 | 65 |
The board authorized a share repurchase program. 2 filings on it so far.
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 5.85 | 5.71 | −2.39% | — |
| Q2 FY2026 | 6.97 | 7.27 | +4.32% | +2.75% |
| Q1 FY2026 | 7.01 | 5.82 | −16.92% | −0.53% |
| Q4 FY2025 | 7.33 | 7.70 | +5.05% | +6.37% |
| Q3 FY2025 | 7.33 | 7.16 | −2.35% | +9.19% |
| Series | 1W | 1M |
|---|---|---|
| UTHR | +3.8% | +12.3% |
| Peers | +2.2% | +7.4% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 43 | 65 |
